THE MANY FACES OF MONOCLONAL GAMMOPATHIES
|
|
|
- Samantha Wright
- 8 years ago
- Views:
Transcription
1 THE MANY FACES OF MONOCLONAL GAMMOPATHIES Marion S. Sternbach, MD, FRCP(C), FACP Presented at Medicine Grand Rounds, St Joseph s Hospital Sept 19, 2007
2 Monoclonal Gammopathies Objectives. 1. Getting acquainted with varied aspects of clinical presentation of the Monoclonal Gammopathies (MG) and their association with different conditions. 2. Following the evolution and pathogenesis from MGUS to myelomas or lymphomas.
3 The immunoglobulin molecule The basic structure of immunoglobulins C C Fc Receptor Region Heavy Chain (gamma, miu, alpha Delta) C C Hinge or J region S-S bridges Light Chain ( kappa, lambda) N N N N Fab. Antibody binding site regions
4 The antibody producing and secreting cells B-Lymphocytes ( CD19,20) Immunoglobulins in cytosol and surface Plasma cell
5 Monoclonal Gammopathies Medicine involves a life time of learning, not only because treatments change and improve constantly, but because NO TWO PATIENTS ARE IDENTICAL & THE SAME DIAGNOSIS PLAYS ITSELF OUT DIFFERENTLY IN EVERY PATIENT.
6 Monoclonal Gammopathies, Definition A monoclonal expansion of a single NON FUNCTIONAL ANTIBODY, originating in a mutated MONOCLONAL B- LYMPHOCYTE or PLASMA CELL. Plasma cells are terminal non proliferating cells, secreting gamma globulins = functional antibodies. Once they mutated, they can proliferate producing the pathological antibody.
7 Monoclonal Antibodies Patient presentations 1. FH, 46 year old female, dental assistant, never exposed to toxic chemicals, fumes or pollutants. Experienced fatigue, full physical check up by family MD and investigations revealed an abnormal protein electrophoresis. Referred to Hematology. Physical Exam WNL, Past History non contributory, exc. For years of smoking, quit 2 years ago.
8 Monoclonal Gammopathies, Patient presentations ( 1. cont.) Investigations: CBC, Renal, Hepatic functions N. Immune fixation: Monoclonal IgGK of 15 g/l. Bone Marrow aspirate and biopsy perfectly Normal. Skeletal survey, chest X ray, abdominal and pelvic US Normal. Pt. followed for 3 ½ years with no change. Then sudden back pain in the T6-T7 area.
9 Monoclonal Gammopathies Patient presentation (1. cont.) All tests from before unchanged, exc. IgGK now up to 21 g/l., Skeletal survey showed a collapsed T6 vertebra. Bone marrow aspirate and biopsy Normal. MRI of spine showed lytic lesion in T6, nowhere else. Vertebral biopsy confirmed Plasmacytoma. VAD chemotherapy administered for 6 cycles with monthly Pamidronate, followed by Autologous PBSC transplant. Successful.
10 Monoclonal Gammopathies Patient presentation year old female from Poland, retired teacher. Suffered for years from Mixed Connective Tissue disorder. Got intermittent steroid therapy. Ref. to me for monoclonal gammopathy IgGL Initial investigations, including BM Bx, skeletal survey, CT-s all Neg. Two years later, followed regularly developed significant lymphadenopathy and splenomegaly.
11 Monoclonal Gammopathies Patient presentation (2. cont.) Lymph node and Bone marrow biopsy revealed low grade diffuse lymphocytic lymphoma. Treated with Cyclophosphamide, Vincristine, Prednisone 8 cycles. Improved remarkably for over one year. Even the Mixed Conn. Tissue Dis. Symptoms abated. 18 months later huge lymph nodes, aggressive large cell lymphoma and Hypercalcemia. CHOP chemotherapy, short remission. Died in one year.
12 Monoclonal Gammopathies, Lymphocytic lymphoma, diffuse
13 Monoclonal Gammopathies Large Cell diffuse Lymphoma
14 Monoclonal Gammopathies Patient presentations year old African female from Congo, immigrated to Canada to 25 year old daughter. Ref. because of extreme weight loss, weakness, diarrheas, peripheral lymphadenopathy and IgGK of 32 g/l. Exam: confirmed diffuse lymphadenop., large tonsils, splenomegaly. Bone marrow: heavy infiltration with plasma cells with mostly kappa surface immuno globulin. No skeletal lesions, HIV positive.
15 Monoclonal Gammopathies Patient presentations 3. (cont.) Ref. by me to STD Clinic at McMaster. Started aggressive HIV therapy, since Myeloma could not be treated until HIV was not under control. Dramatic response to Anti-HIV DNA treatment: Clinically gained weight, felt well. Lab: PCR dramatic reduction of viral load and increase of Helper Lymphocytes. Reduction and final disappearance of monoclonal gammopathy.
16 Monoclonal Gammopathies at the Mayo Clinic patients 3% 2 % 1 % 3 % 4 % 10% 14 % 63% MGUS Myeloma Amyloid SMM Lymphom Macrogl. Extramed other
17 Classification of Monoclonal Gammopathies 1. Monoclonal gammopathies of undetermined significance (MGUS): IgG, IgA, IgM, IgD almost always will evolve into aggressive Myeloma. Idiopathic light chain Bence Jones proteinuria.
18 Classification of Monoclonal Gammopathies ( 2 cont. ) Bi- & triclonal Gammopathies, A. Malignant Monoclonal Gammopathies: 1. Myeloma, 2. Smoldering myeloma, 3. Plasma cell leukemia, 4. Non secretory myeloma. 5. Osteosclerotic myeloma (POEMS)
19 Classification of Monoclonal Gammopathies ( cont.3 ) B. Plasmacytoma: 1. Solitary Plasmacytoma of bone 2. Extramedullary plasmacytoma. C. Lymphoproliferative disorders : 1. Waldenstrom s Macroglobulinemia, 2. Heavy chain diseases (HCD): gamma, alpha, miu (u) 3. Primary Amyloidosis. 4. CLL and other B- cell Lymphomas, PTLD
20 IgG Myeloma in bone marrow
21 Classification of Monoclonal Gammopathies ( cont. 4 ) D. Connective Tissue disorders: SLE, Rheumatoid Arthritis, Sjogren syndrome and Mixed conn. Tissue Disorders, Scleroderma, Psoriatic Arthritis, Polymyalgia rheumatica, Cryoglobulinemia.
22 Cryoglobulinemia rash on legs
23 Classification of Monoclonal Gammopathies ( cont. 5 ) E. Associated with infections: Hepatitis C virus, HIV/AIDS F. Dermatologic disorders: Scleredema, Lichen myxoedematosus, Diffuse plane xanthomatosis, Urticaria and IgM ( Schnitzler s syndrome ) Subcorneal pustular dermatosis, Necrobiotic xantogranuloma. Pyoderma gangrenosum
24 Classification of Monoclonal Gammopathies, ( cont. 6 ) G. Miscellaneous: Acquired von Willebrand s syndrome with Anti Factor VIII Ag. Activity. Acquired C 1 esterase deficiency ( angioedema ) Eosinophilic Fasciitis, Myelodysplasia, Chronic Neutrophilic Leukemia, CIDP with MGUS, Capillary Leak syndrome, T-cell large granular lymphocyte leukemia.
25 Monoclonal antibody Anti-F.X
26 Course of 241 pts. With MGUS from Kyle, RA: JAMA 251:1849, 1984 Group Description F/U yrs No. of pts. % 1 No substantial increase of serum or urine monoclonal protein Monoclonal protein =>3.0g/dl, but no myeloma or related disease Died of unrelated causes Development of Myeloma, macroglob. Amyloidosis or related disease Total
27 Monoclonal Gammopathies of undetermined significance (MGUS) Diagnostic Criteria: 1.Presence of a Monoclonal antibody : IgG, A, or M at a concentration of < 3.0 g/dl. 2. Less than 10% plasma cells in bone marrow. 3. Absence of: Predilection of developing myeloma Anemia, or related malignancy at a rate of Lytic bone lesions, 1% per year. Renal impairment, Hypercalcemia No evidence of underlying plasma or lymphoproliferative disorder.
28 Monoclonal Gammopathies Serum Protein Electrophoresis. + M-protein _ Albumin alpha1 alpha2 beta gamma globulins
29 Monoclonal Gammopathies, Incidence and Clinical Characteristics MGUS is found in 1-2% of adults in studies from Sweden, US, France and Japan. It becomes higher after the age of 70 yrs and 3-4 X higher in African Americans than Caucasians. Prevalence of MGUS in Olmsted county, Minnesota: Immunofixation in 21,463/ 28,038 residents (77%) of persons > 50 yrs. Jan :
30 Prevalence of MGUS in Olmsted county Minnesota => 50 years 3.2% => 70 years 5.3% => 85 years 7.5% Men : Women ratio = 4.0 : 2.7% MGUS concentration: < 1.0 g/dl in 63% IgG - 69% IgA - 11% =>2.0 g/dl in 4.5% IgM 17% Biclonal 3% kappa -62 and lambda 38%
31 Monoclonal Gammopathies Clinical course by Mayo Clinic Derived from long term F/U of 1,384 patients with MGUS 11,009 person-years during which 70% pts. Died % developed Myeloma, Macroglob., Amyloidosis or Lymphoma. Cumulative probability of progression to one of those dis. was: 10 yrs 10%, This is where the average 20 yrs. - 21% of 1% per year was calculated. 25 yrs 26%
32 Monoclonal Gammopathies Clinical Course continued Number of pts. With MGUS progressing to plasma cell or lymphoid neoplasia was 7.3 X that expected in the general population. Median interval from Dg. Of MGUS to one of its complications was 10.4 years. 32 pts. (2.3%) had a serum M-protein of =>3.g/dl and >10% plasma cell in the bone marrow without developing Myeloma. Only 6 pts.(0.4%) had MGUS, that spontaneously disappeared.
33 Monoclonal Gammopathies Predictors of progression A. Low risk: 1. M-protein < 1.5 g/dl 2. Marrow plasma cells < 5.0% 3. No reduction in polyclonal immunoglobulins. 4. No light chain proteinuria. 5. ESR < 40 mm/hr 6. High IgA and IgM monoclonal protein have a significant risk for progression. 7. K or L light chains don t seem to impact on progression.
34 Monoclonal Gammopathies Risk stratification model. B. Free Light Chain (FLC) proteinuria or in serum carries a high risk of progression to MM, or Amyloidosis, confirmed in a cohort of 1,148 pts. Hazard ratio: 3.5; 95% CI Indep. Of size and type of serum M protein. 3 adverse risk factors: 1. Serum M protein > 1.5 g/l 2. Abnormal FLC ratio 3. Non-IgG MGUS
35 Monoclonal Gammopathies Risk stratification model (cont.) 3 risk factors ( high risk MGUS )- 58% 2 risk factors ( high-interm. MGUS) 37% 1 risk factor ( low-interm. MGUS ) - 21% No risk factor ( low risk MGUS ) 5 % The higher the M-protein concentration the higher the risk of progression to plasma cell or lymphoid neoplasias.
36 Immuno fixation of MGUS on Agarose Gel Serum prot. Eph. Alb. Alpha 1, +2 beta, M-prot gamma Ig G Kappa IgA Lambda
37 Monoclonal Gammopathies Evaluation of Asymptomatic MGUS CBC Urea, Creatinine, Calcium, Phosphorus and Uric Acid Serum protein Electrophoresis and immunofixation Quantitative Immunoglobulins 24 hour urine for total protein and light chains. Bone marrow biopsy and aspiration if MGUS is => 1.5 g/dl Metastatic skeletal survey. Monitoring every 6 months with careful history and phisical exam, lab. Testing for the rest of the pts. Life.
38 Monoclonal Gammopathies Speculation on their pathogenesis. 1. Chronic Antigenic stimulation as in HIV Hepatitis or other longstanding chronic infections and skin diseases. 2. Environmental Factors: Osserman had an inbred mouse highly susceptible to develop Plasmacytomas. If these mice were kept in a strictly sterile environment from birth, they did not develop the plasmacytoma.
39 Monoclonal Gammopathies Speculation on their pathogenesis.2 3. Evolution from auto-antibodies in autoimmune diseases or from hyperpolyclonal gamma globulinemia to MGUS. 4. As age progresses immune surveillance diminishes. 1 in 1.0 X 10^6 cells is usually mutated, but gets eliminated by our cytotoxic lymphocytes and mono-macrophages. These defenses start failing with age and neoplasia is more frequent in elderly.
40 IgA Myeloma in bone marrow
41 Current Therapies for Myeloma 1. Induction therapy with Vincristine, Adriamycine and Dexamethasone, 2. Harvesting of peripheral blood stem cells (PBSC) through apheresis, 3. High dose chemotherapy with Melphalan +/- TBI only if necessary. 4. After relapse Thalidomide and Prednisone, followed by 5. Bortezomib (Velcade) have been very successful.
42 Monoclonal Gammopathies Summary The prevalence of MG is high and increases with age after the 6-th decade. 2. Its potential and susceptibility to evolve at 1.0 to 1.5 % per year into a plasmacytoid or lymphoid neoplasia is high: 7.3 X from the base line in an unaffected population of the same age group.
43 Monoclonal Gammopathies (MG) Summary MG is often associated with underlying nonlympho-plasmacytoid disorders, which when treated successfully, lead also to the disappearance of the MG. 4. Diff. Dg. Of MGUS from Myeloma : MG < 30 g/l Plasma cells in bone marrow < 10 % NO Anemia, NO Hypogammaglobulinemia, NO renal failure and urine light chain proteinuria. NO hypercalcemia, NO lytic bone lesions. NO CD 56 markers on plasma cells.
44 Monoclonal Gammopathies Summary 3. Life long periodic monitoring of MG, as well as searching for an underlying or associated disorder is extremely important, since when they evolve into lymphomas or myelomas these diseases can be very successfully treated.
Multiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
FastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
MULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology
MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
Multiple Myeloma Patient s Booklet
1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple
SOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008
Introduction This disease site includes the following three malignancies: multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia. See pages 4 and 5 for descriptions of the latter two diseases.
Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma.
Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma. The intent is to positively identify patients with active or
Proteins. Protein Trivia. Optimizing electrophoresis
Proteins ELECTROPHORESIS Separation of a charged particle in an electric field Michael A. Pesce, Ph.D Department of Pathology New York-Presbyterian Hospital Columbia University Medical Center Rate of migration
Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts
Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts Normal plasma cells (a type of white blood cell) produce antibodies (also known as immunoglobulins) which help fight infection. Each type
Multiple Myeloma Making Sense of the Report Forms. Parameswaran Hari Medical College of Wisconsin Milwaukee
Hodgkin CML MDS/Other Leuk CLL Neuroblastoma Multiple Myeloma Making Sense of the Report Forms Parameswaran Hari Medical College of Wisconsin Milwaukee Indications for Blood and Marrow Transplantation
Investigation of B cell malignancies. Dr. Joanna Sheldon Protein Reference Unit St. George s s Hospital
Investigation of B cell malignancies Dr. Joanna Sheldon Protein Reference Unit St. George s s Hospital The B cell progression from «Pluripotent stem cell «Lymphoid committed stem cell «B lineage committed
TABLE OF CONTENTS. Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data
Instructions for Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data (Form 2016) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Multiple Myeloma /
Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
Whole Antibody and Free Light Chain Production by Plasma Cells
MYELOMA Very Good ; Stringent or Complete Navigating the maze of Responses Parameswaran Hari Medical College of Wisconsin Milwaukee Increasing understanding of disease biology in the last few years Deeper
A Clinical Primer. for Managed Care Stakeholders
reviews therapy Diagnosing, Staging, and Treating Multiple Myeloma: A Clinical Primer for Managed Care Stakeholders by Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders
Things You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
Use of free light chain analysis in the diagnosis, prognosis and therapy of multiple myeloma. Amitabha Mazumder, MD
Use of free light chain analysis in the diagnosis, prognosis and therapy of multiple myeloma Amitabha Mazumder, MD Monoclonal Gammopathies Multiple Myeloma 18% Light Chain Dep Ds < 1% AL Amyloidosis 9%
I've Just Been Diagnosed. with Multiple Myeloma, What s Next?
I've Just Been Diagnosed with Multiple Myeloma, What s Next? Table of Contents Message from a Survivor Introduction What is Multiple Myeloma? What Causes Multiple Myeloma? Genes & Multiple Myeloma What
Outline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD
Outline A Disease Overview June 3, 2013 Andrew Eisenberger, MD Assistant Professor of Medicine Hematology/Oncology Columbia Presbyterian Medical Center Introduction Epidemiology/Risk Factors Clinical Features/Diagnostic
Plasma cell dyscrasias Mark Drayson
Plasma cell dyscrasias Mark Drayson Mortality statistics for England and Wales. Deaths attributed to multiple myeloma from 1988-1997 by age cohort as a percentage of total (21,257) deaths Deaths in age
Stem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
NATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
Understanding Protein Electrophoresis
Understanding Protein Electrophoresis International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic
Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells
MULTIPLE MYELOMA. Overview
MULTIPLE MYELOMA Overview Steven R. Schuster, M.D. May 7, 2015 Objectives Give an overview of Multiple Myeloma Everything I know in 15 minutes Explain how genetic information can be used to personalize
Background Information Myeloma
Myeloma FAST FACTS Myeloma, also known as multiple myeloma, is a type of cancer that develops from plasma cells which originate in the bone marrow 1 Myeloma is the second most common type of blood cancer
Myeloma pathways to diagnosis UCLP audit
Myeloma pathways to diagnosis UCLP audit Dr Neil Rabin Consultant Haematologist University College London Hospitals & North Middlesex University Hospital Myeloma Clinical Features Bone pain (70%) High
Table of Contents Accelerate Your Research Introduction I. From the Real World to the Lab II. Research Challenges III. How Can Conversant Bio Help?
Table of Contents Accelerate Your Research 2 Introduction 3 I. From the Real World to the Lab 4 A. Diagnosing Multiple Myeloma 4 1. Lab Tests 4 2. Bone Marrow Exams 6 3. Imaging Studies 7 B. Subtypes of
Understanding Protein Electrophoresis
Understanding Protein Electrophoresis International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
Understanding Serum Free Light Chain Assays
Understanding Serum Free Light Chain Assays International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax:
Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine.
Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine Multiple Myeloma Associate professor Abduyeva F.M., MD, PhD 2014 Definition Multiple
Waldenström Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment
NOVEMBER 2006 IMPROVING PATIENT CARE THROUGH ESOTERIC LABORATORY TESTING VOLUME 31, NO. 11 Monoclonal Gammopathy of Undetermined Significance, Waldenström Macroglobulinemia, AL Amyloidosis, and Related
New diagnostic criteria for myeloma
New diagnostic criteria for myeloma Dr Guy Pratt Senior Lecturer/Honorary Consultant Haematologist University of Birmingham/Heart of England NHS Trust International Myeloma Working Group (IMWG) define
Multiple. Powerful thinking advances the cure
Multiple Myeloma DISEASE OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)
Serum Protein Electrophoresis
Serum Protein Electrophoresis Karina Rodriguez-Capote MD, PhD, FCACB, Clinical Chemist, DynaLIFE Dx 2013 Laboratory Medicine Symposium Objectives Describe the electrophoresis procedure used to separate
Protein electrophoresis is used to categorize globulins into the following four categories:
Globulin Globulin is one of the two types of serum proteins, the other being albumin. This generic term encompasses a heterogeneous series of families of proteins, with larger molecules and less soluble
Mansour Al-Hiary MD *, Baheieh Al-Abbadi MD*, Nesreen Abu Hazeem MD*, Ali Swailmeen MD**, Najah Aldrous MD*, Nazmi Kamal MD* ABSTRACT
Pattern of Serum Protein Electrophoresis Results in a Group of Patients with Plasma Cell Myeloma Confirmed by Bone Marrow Findings at King Hussein Medical Center Mansour Al-Hiary MD *, Baheieh Al-Abbadi
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline Introduction ASCO convened an Update Committee to review and update the 2002 recommendations for the role of bisphosphonates
specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
A Science Writer s Guide to Multiple Myeloma
A Science Writer s Guide to Multiple Myeloma 1 A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma PREFACE Blood cancers and related disorders a serious health risk
Multiple Myeloma Patient Handbook. www.myeloma.ca
Multiple Myeloma Patient Handbook www.myeloma.ca Introduction This resource has been designed for: 1. Someone who has been newly diagnosed with myeloma and is wondering what it means and what the future
Patient Handbook. Multiple Myeloma. International Myeloma Foundation. Until There is a Cure... There is the IMF. Cancer of the Bone Marrow
Until There is a Cure... There is the IMF. Patient Handbook Published by the International Myeloma Foundation (IMF) International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA
NON SECRETORY MULTIPLE MYELOMA A CASE REPORT
NON SECRETORY MULTIPLE MYELOMA A CASE REPORT Golwilkar A.,*Saluja R., Mehendale A. and Jalnapurkar N. Department of Histopathology, Golwilkar Metropolis Health Services (India) Pvt Ltd *Author for Correspondence
Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH
Lymphoplasmacytic Lymphoma versus IGM Multiple Myeloma Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Hematology consult patient 48 yo woman presents to ER with nonspecific complaints:
Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
A Focus on Multiple Myeloma
A Focus on Multiple Myeloma Guest Expert: Madhav Dhodapkar, MD Professor of Hematology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr.
Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
Cleveland Clinic Taussig Cancer Institute s Multiple Myeloma Program
Cleveland Clinic Taussig Cancer Institute s Multiple Myeloma Program Our mission The primary mission is to provide patients and physicians access to innovative treatment options, medical expertise, and
Rheumatology Labs for Primary Care Providers. Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine
Rheumatology Labs for Primary Care Providers Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine Objectives Review the Indications for and Interpretation of lab testing for the following diseases:
Chapter 2. S. Hovenga 1, J.Th.M. de Wolf 1, J.E.J. Guikema 4, H. Klip 2, J.W. Smit 3, C.Th. Smit Sibinga 5, N.A. Bos 4, E.
Chapter 2 Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses; a high incidence of oligoclonal serum immunoglobulins post transplantation S. Hovenga, J.Th.M. de Wolf, J.E.J.
Information Pathway. Myeloma tests and investigations. Paraprotein measurement
Information Pathway Myeloma UK Broughton House 31 Dunedin Street Edinburgh EH7 4JG Tel: + 44 (0) 131 557 3332 Fax: + 44 (0) 131 557 9785 Myeloma Infoline 0800 980 3332 www.myeloma.org.uk Charity No. SC
What you need to know about. Multiple Myeloma. Based on a brochure from National Institutes of Health National Cancer Institute STDAVIDS.
What you need to know about Multiple Myeloma Based on a brochure from National Institutes of Health National Cancer Institute STDAVIDS.COM What you need to know about Multiple Myeloma Introduction...1
Plasma Cell Disorders
Plasma Cell Disorders 2015 Subtypes of Plasma Cell Disorders Increased Plasma Cells Monoclonal Gammopathy Myeloma Macroglobulinemia (IgM) Increased / Altered Products of Plasma Cells Light Chain Amyloidosis
Date for guideline review January 2010. Avon Haematology Unit, Bristol Haematology and Oncology Centre, Bristol
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): Guidelines for the investigation of newly detected M-proteins and the management of Monoclonal Gammopathy of Undetermined Significance (MGUS)
PATIENT HANDBOOK. Multiple Myeloma. Improving Lives Finding the Cure. Cancer of the Bone Marrow. Prepared by Brian G.M. Durie, M.D.
PATIENT HANDBOOK A Publication of the International Myeloma Foundation Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure. Prepared by Brian G.M.
Asymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells
ESSENTIALS Multiple Myeloma Diagnosed with Multiple Myeloma? It s important to understand everything you can about your diagnosis, possible treatments, and places to go for support and care. Cancer is
Myeloma. Anne Grace, myeloma survivor. Support for this publication provided by
Myeloma Anne Grace, myeloma survivor Support for this publication provided by Revised 2015 Publication Update Myeloma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
Multiple Myeloma How to Evaluate Response To Treatment and Relapse
Multiple Myeloma How to Evaluate Response To Treatment and Relapse D R L. G AR D E R E T Saint Antoine Hospital, Paris Haematology Department 1 What is Multiple Myeloma? 4 Diagnostic Tools 8 Response to
Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
Myeloma. Ann Grace, myeloma survivor. This publication was supported in part by a grant from
Myeloma Ann Grace, myeloma survivor This publication was supported in part by a grant from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma
Aggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
Multiple Myeloma Understanding your diagnosis
Multiple Myeloma Understanding your diagnosis Multiple Myeloma Understanding your diagnosis When you first hear that you have cancer you may feel alone and afraid. You may be overwhelmed by the large amount
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
Multiple Myeloma. What is cancer?
What is cancer? Multiple Myeloma The body is made up of trillions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly way. During the early years of a person's life,
MYEL NEWL OMA Y DIA GNOSED
Information on NEWLY DIAGNOSED MYELOMA UAMS 1 ABOUT THE MYELOMA INSTITUTE The Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS) is a leading center in the world for comprehensive
Glossary of Multiple Myeloma Terms
Some things that make multiple myeloma (MM) difficult to understand are the unfamiliar medical terms that some experts and healthcare providers use to explain it. You may come across words like these when
Chapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
Myeloma. A guide for patients, families and whanau
Myeloma A guide for patients, families and whanau The Leukaemia & Blood Foundation is grateful to Janssen for sponsoring this booklet 1 CONTENTS PAGE Introduction 2 The Leukaemia & Blood Foundation 3 Bone
The Immune System: A Tutorial
The Immune System: A Tutorial Modeling and Simulation of Biological Systems 21-366B Shlomo Ta asan Images taken from http://rex.nci.nih.gov/behindthenews/uis/uisframe.htm http://copewithcytokines.de/ The
Myeloma. A guide for patients and families. 1800 620 420 leukaemia.org.au
Myeloma A guide for patients and families 1800 620 420 leukaemia.org.au Notes Contents Acknowledgments 4 Introduction 5 The Leukaemia Foundation 6 Blood cancers 10 What is myeloma? 16 Who gets myeloma?
In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
Introduction. Plasma Cell Neoplasms: Diagnosis. Dr. Kevin Imrie Updated August 2007. Updates (extensive re-write):
Plasma Cell Neoplasms Dr. Kevin Imrie Updated August 2007 Updates (extensive re-write): Major changes to initial therapy of younger and older patients Use of thalidomide, bortezomib Changes to bisphosphonate
Intérêt t clinique de l'identification des
Intérêt t clinique de l'identification des chaînes légères l libres Jean-Fran François Lambert Hematologie - CHUV Healthy 69 yo female Negative past medical history 2/07 acute pulmonary edema Progressive
Multiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.
Multiple Myeloma Introduction Multiple myeloma is a type of cancer that affects white blood cells. Each year, thousands of people find out that they have multiple myeloma. This reference summary will help
Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
Serum protein electrophoresis is a laboratory
Understanding and Interpreting Serum Protein Electrophoresis THEODORE X. O CONNELL, M.D., TIMOTHY J. HORITA, M.D., and BARSAM KASRAVI, M.D. Kaiser Permanente Woodland Hills Family Medicine Residency Program,
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
Multiple Myeloma F1 蘇 勇 誠 /MA 林 棟 樑 2007-3-28
Multiple Myeloma F1 蘇 勇 誠 /MA 林 棟 樑 2007-3-28 Plasma Cell Disorders Multiple Myeloma Other Disorders Monoclonal gammopathy of undetermined significance (MGUS) Smoldering multiple myeloma (SMM) Solitary
Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
Appendix D- Monoclonal Gammopathy of Undetermined Significance (MGUS)
Local Enhanced Service: Primary care management of stable haematological patients Monoclonal Gammopathy of Undetermined Significance (MGUS) 1. Introduction Monoclonal Gammopathy of Undetermined Significance
WM: Managing the Side Effects of Treatment
WM: Managing the Side Effects of Treatment 2014 IWMF Educational Forum Jeffrey V. Matous, MD Colorado Blood Cancer Institute www.bloodcancerinstitute.com Tampa, FL May 17, 2014 Determining a side effect
Bone Disease in Myeloma
Bone Disease in Myeloma Washington, DC August 8, 2009 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma Vascular Cytokines
Extramedullary Plasmacytoma
Extramedullary Plasmacytoma Carole Fakhry MD MPH The Milton J. Dance, Jr. Head and Neck Center at GBMC HEAD AND NECK GRAND ROUNDS 9-5-2008, Baltimore, Maryland Plasmacytoma Monoclonal proliferation of
Multiple. Powerful thinking advances the cure
Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)
Bone Disease in Myeloma. St. Petersburg, Russia September 16, 2009
Bone Disease in Myeloma St. Petersburg, Russia September 16, 2009 Bi Brian G.M. GMDurie, M.D. MD Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Authors Ronald C. Walker 1,2, Tracy L. Brown 3, Laurie B. Jones-Jackson
Multiple Myeloma. What is multiple myeloma? Low blood counts
Multiple Myeloma What is multiple myeloma? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas of the
LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation: